<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">V</forename><surname>Naranbhai</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Centre for the AIDS Programme of Research in South Africa (CAPRISA)</orgName>
								<orgName type="institution">University of KwaZulu-Natal</orgName>
								<address>
									<settlement>Durban</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">HIV Pathogenesis Programme</orgName>
								<orgName type="institution" key="instit2">University of KwaZulu-Natal</orgName>
								<address>
									<settlement>Durban</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>De Assis Rosa</surname></persName>
							<idno type="ORCID">0000-0003-4281-8882</idno>
							<affiliation key="aff1">
								<orgName type="institution">National Institute of Communicable Diseases</orgName>
								<address>
									<settlement>Sandringham</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">L</forename><surname>Werner</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Centre for the AIDS Programme of Research in South Africa (CAPRISA)</orgName>
								<orgName type="institution">University of KwaZulu-Natal</orgName>
								<address>
									<settlement>Durban</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Moodley</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">HIV Pathogenesis Programme</orgName>
								<orgName type="institution" key="instit2">University of KwaZulu-Natal</orgName>
								<address>
									<settlement>Durban</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Hong</surname></persName>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Kharsany</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Centre for the AIDS Programme of Research in South Africa (CAPRISA)</orgName>
								<orgName type="institution">University of KwaZulu-Natal</orgName>
								<address>
									<settlement>Durban</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">K</forename><surname>Mlisana</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Centre for the AIDS Programme of Research in South Africa (CAPRISA)</orgName>
								<orgName type="institution">University of KwaZulu-Natal</orgName>
								<address>
									<settlement>Durban</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Sibeko</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Centre for the AIDS Programme of Research in South Africa (CAPRISA)</orgName>
								<orgName type="institution">University of KwaZulu-Natal</orgName>
								<address>
									<settlement>Durban</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">N</forename><surname>Garrett</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Centre for the AIDS Programme of Research in South Africa (CAPRISA)</orgName>
								<orgName type="institution">University of KwaZulu-Natal</orgName>
								<address>
									<settlement>Durban</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Chopera</surname></persName>
						</author>
						<author>
							<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Carr</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">HIV Pathogenesis Programme</orgName>
								<orgName type="institution" key="instit2">University of KwaZulu-Natal</orgName>
								<address>
									<settlement>Durban</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Q</forename><forename type="middle">Abdool</forename><surname>Karim</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Centre for the AIDS Programme of Research in South Africa (CAPRISA)</orgName>
								<orgName type="institution">University of KwaZulu-Natal</orgName>
								<address>
									<settlement>Durban</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><forename type="middle">V S</forename><surname>Hill</surname></persName>
						</author>
						<author>
							<persName><forename type="first">S</forename><forename type="middle">S Abdool</forename><surname>Karim</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Centre for the AIDS Programme of Research in South Africa (CAPRISA)</orgName>
								<orgName type="institution">University of KwaZulu-Natal</orgName>
								<address>
									<settlement>Durban</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Altfeld</surname></persName>
						</author>
						<author>
							<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Gray</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">National Institute of Communicable Diseases</orgName>
								<address>
									<settlement>Sandringham</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">T</forename><surname>Ndung'u</surname></persName>
							<email>ndungu@ukzn.ac.za</email>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">HIV Pathogenesis Programme</orgName>
								<orgName type="institution" key="instit2">University of KwaZulu-Natal</orgName>
								<address>
									<settlement>Durban</settlement>
									<country key="ZA">South Africa</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">0DC7387C3B1140267F5C87695A6321D2</idno>
					<idno type="DOI">10.1186/s12879-016-1361-1</idno>
					<note type="submission">Received: 13 August 2015 Accepted: 18 January 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:15+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>KIR</term>
					<term>HLA</term>
					<term>HIV</term>
					<term>Acquisition</term>
					<term>Viral control</term>
					<term>Disease progression</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Killer-cell Immunoglobulin-like Receptors(KIR) interact with Human Leukocyte Antigen(HLA) to modify natural killer-and T-cell function.</s><s>KIR are implicated in HIV acquisition by small studies that have not been widely replicated.</s><s>A role for KIR in HIV disease progression is more widely replicated and supported by functional studies.</s></p><p><s>Methods: To assess the role of KIR and KIR ligands in HIV acquisition and disease course, we studied at-risk women in South Africa between 2004-2010.</s><s>Logistic regression was used for nested case-control analysis of 154 women who acquired vs. 155 who did not acquire HIV, despite high exposure.</s><s>Linear mixed-effects models were used for cohort analysis of 139 women followed prospectively for a median of 54 months (IQR 31-69) until 2014.</s></p><p><s>Results: Neither KIR repertoires nor HLA alleles were associated with HIV acquisition.</s><s>However, KIR haplotype BB was associated with lower viral loads (−0.44log10 copies/ml;SE = 0.18;p = 0.03) and higher CD4+ T-cell counts(+80 cells/ μl;SE = 42;p = 0.04).</s><s>This was largely explained by the protective effect of KIR2DL2/KIR2DS2 on the B haplotype and reciprocal detrimental effect of KIR2DL3 on the A haplotype.</s><s>Conclusions: Although neither KIR nor HLA appear to have a role in HIV acquisition, our data are consistent with involvement of KIR2DL2 in HIV control.</s><s>Additional studies to replicate these findings are indicated.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p><s>An array of host genetic factors have been reported to alter HIV acquisition or markers of HIV disease progression <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</s><s>Identifying and understanding these genetic correlates may accelerate preventive and therapeutic efforts.</s></p><p><s>The most widely replicated correlates of HIV acquisition include homozygosity in the 32-base pair deletion in CCR5 that reduces acquisition risk.</s><s>Although, in comparison, greater effort has been focused on identifying correlates of HIV disease progression there are similarly only a handful of widely replicated findings.</s><s>Natural Killer (NK) cell and CD8+ T-cell responses stand out as being reproducibly implicated in HIV control <ref type="bibr" target="#b2">[3]</ref>.</s><s>Concordantly, variation in the Human Leukocyte Antigen (HLA) and Killer-cell Immunoglobulin-like Receptor (KIR) loci, the two most polymorphic regions of the human genome that encode receptors involved in NK and CD8+ T-cell function, is associated with rates of HIV disease progression across several studies <ref type="bibr" target="#b1">[2]</ref>.</s><s>Genome-wide association studies identify HLA-B*57 alleles, and variants that affect HLA-C expression <ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref> as important modifiers of HIV viraemia, the former of which had been identified in many earlier candidate gene studies.</s></p><p><s>Natural Killer cells are amongst the earliest responders to viral infection and mediate protective responses by secreting pro-inflammatory cytokines and by direct cytolysis of infected cells.</s><s>Their function is governed, at least in part, by the combinatorial array of inhibitory and activating receptors including the KIR, Leukocyte immunoglobulin-like receptors (LILR), the C-type lectin receptors-NKG2A-F, and the natural cytotoxic receptors (NCRs) -NKp30, NKp44 and NKp46.</s><s>The dominant regulators of NK cell recognition of virus-infected cells are thought to be KIR, because these are the natural receptors for HLA class I <ref type="bibr" target="#b6">[7]</ref>.</s><s>Alteration in HLA expression and presentation of pathogen-derived or self-peptides is a common feature of many viral infections <ref type="bibr" target="#b7">[8]</ref>.</s><s>Diversity in KIR gene content, polymorphism and structural variation within the 14 KIR genes, and variation in expression confer additional variation in the ability of NK cells to identify and respond to virus-infected cells.</s><s>KIRs show partial specificity in their recognition of HLA ligands: KIR3DL1 and KIR3DS1 recognise HLA-A and HLA-B molecules with the Bw4 epitope, KIR2DL1 recognises HLA-C molecules of the C2 group exclusively, KIR2DL3 recognises HLA-C of the C1 group exclusively and KIR2DL2 recognizes HLA-C of both C1 and C2 groups.</s><s>The KIR genes segregate in two groups of haplotypes.</s><s>Group A haplotypes consist of nine genes that encode predominantly inhibitory receptors, whereas group B haplotypes represent a more diverse collection of haplotypes based on gene content and contain more activating KIRs compared with haplotype A.</s></p><p><s>Several combinations of KIR and HLA have been associated with protection from HIV acquisition <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref>, though these findings are based on small sample sizes and none have been replicated in the literature.</s><s>In contrast, a large study reported in 2002, found that KIR3DS1 together with HLA Bw4 alleles encoding Isoleucine at position 80 (80I) are associated with slower disease progression <ref type="bibr" target="#b4">[5]</ref>.</s><s>Several additional lines of evidence from subsequent observational and functional studies support a role for KIR in HIV control.</s><s>NK cells are expanded in primary HIV infection <ref type="bibr" target="#b13">[14]</ref>, the expansion is modified by specific KIR and ligand repertoires <ref type="bibr" target="#b14">[15]</ref>, the degree of HLA C ligand expression associates with protection <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b15">16]</ref> and viruses sequenced from individuals with specific KIR show evidence of 'escape' mutation at sites that appear to alter recognition by KIR <ref type="bibr" target="#b16">[17]</ref>.</s><s>As in infection with EBV <ref type="bibr" target="#b17">[18]</ref>, CMV <ref type="bibr" target="#b18">[19]</ref>, HCV or HTLV-1 <ref type="bibr" target="#b19">[20]</ref>, KIR have also been shown to modulate Tcell responses to HIV <ref type="bibr" target="#b20">[21]</ref>.</s></p><p><s>We studied the role of HLA and KIR on risk of HIV acquisition and course of HIV viraemia and CD4+ T-cell counts through the first 5-10 years of infection in South African women infected with HIV-1 clade C in a nested case-control and prospective cohort study respectively.</s><s>In prior studies in this cohort we have reported that a) innate immune cell activation is associated with enhanced HIV acquisition <ref type="bibr" target="#b21">[22]</ref>; b) HIV-directed NK cells secreting IFN-y are associated with reduced HIV acquisition risk <ref type="bibr" target="#b22">[23]</ref>; c) HIV acquisition results in profound alteration in NK cell function <ref type="bibr" target="#b23">[24]</ref> and d) the rate of HIV disease progression is more rapid than similar cohorts elsewhere <ref type="bibr" target="#b24">[25,</ref><ref type="bibr" target="#b25">26]</ref>.</s><s>This current study strongly implicates KIR2DL2, belonging to the group B haplotype with HIV control.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design and cohort accrual</head><p><s>Between 2004 and 2010, we prospectively enrolled and followed-up women at risk for HIV acquisition in studies <ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref> conducted at two urban and one rural site in KwaZulu-Natal, South Africa (Fig. <ref type="figure" target="#fig_0">1</ref>) <ref type="bibr" target="#b25">[26]</ref>.</s><s>We performed two analyses of KIR/HLA genetic profiles: a nested casecontrol analysis of HIV acquisition and a prospective cohort analysis of involvement in HIV disease course.</s><s>For the nested case-control analysis we compared 154 women who acquired HIV to 155 who did not and for the cohort analysis, studied 139 women with viral load and CD4+ Tcell count measures.</s></p><p><s>Women at risk for HIV were extensively counselled on HIV risk reduction and provided with condoms in line with the highest standard of counselling at the time <ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref>.</s></p><p><s>The median age at enrolment was 21 years (IQR 20-26 years).</s><s>As previously reported <ref type="bibr" target="#b29">[30]</ref>, women who acquired HIV were younger than those who remained HIV negative (median age 23, IQR 20-26 vs. median age 33, IQR <ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref>.</s><s>All except one woman in this study self-identified as black-African of Zulu ethnicity.</s></p><p><s>During follow-up in the AI study, clinical care was offered as per contemporary South African treatment guidelines including combination antiretroviral therapy when clinically indicated or if the CD4+ T-cell count declined to below 200 cells/μl or 350 cells/μl (updated according to evolving treatment guidelines).</s><s>Participants were seen according to the following schedule: weekly to fortnightly for the first 3 months post HIV acquisition, monthly from months 3-12 and quarterly thereafter.</s><s>At each visit women received comprehensive prevention counselling, clinical examination, viral load and CD4+ T-cell count measurements and additional clinically indicated investigations performed at an accredited laboratory (ISO15189) using previously described methods <ref type="bibr" target="#b27">[28,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b30">31]</ref>.</s><s>The last possible date of censorship in those who did not reach a progression endpoint was 1 August 2014.</s><s>Women were censored at time of combination antiretroviral therapy (cART) initiation, death, loss to follow-up or withdrawal from the study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics statement</head><p><s>Participants gave their written and informed consent to participation in each study according to protocols approved by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal (Ref 050/051, E013/04, E111/06), and relevant collaborating centres (University of Cape Town 025/2004, University of Witwatersrand M040202).</s></p><p><s>The protocol under which analyses in this study are conducted was independently approved by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal (BE073/10).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>KIR and HLA typing</head><p><s>Killer-cell immunoglobulin-like receptor genotyping was conducted in samples from 154 HIV-positive women and 155 HIV-negative women by sequence-specific oligonucleotide primer PCR or qPCR according to previously described methods <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b31">32]</ref>.</s><s>The definitions used to assign KIR haplotypes based on gene content were based on previous reports <ref type="bibr" target="#b6">[7]</ref> and are described in detail in Additional file 1.</s><s>Individuals having only and all genes of following group were denoted as having AA: KIR3DL3, KIR2DL3, KIR2DL1, KIR2DP1, KIR3DP1, KIR2DL4, KIR3DL1, KIR2 DS4, KIR3DL2.</s><s>Individuals lacking any of the following were denoted as BB: KIR2DL1, KIR2DL3, KIR3DL1, KIR2 DS4.</s><s>Individuals having all A haplotype genes and any 1 of the following genes were presumed to be AB: KIR 2DL2, KIR2DL5, KIR2DS1, KIRDS2, KIR2DS3, KIR 2DS5, KIR3DS1.</s><s>Four-digit HLA typing was performed as previously described.</s><s>Further information on classification of HLA alleles into Bw4 groups and C1/C2 groups is given in Additional file 1.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Outcome definition</head><p><s>Methods of HIV diagnosis and estimation of the date of acquisition have been previously reported <ref type="bibr" target="#b26">[27,</ref><ref type="bibr" target="#b28">29]</ref>.</s><s>Plasma HIV viral load was assessed by Roche Ampliprep/Amplicor or Roche Taqman (Roche Diagnostics, New Jersey, USA).</s><s>CD4+ T-cell count enumeration in whole blood was performed by the TruCOUNT method on a FACSCalibur instrument (BD Biosciences, San Jose, USA).</s><s>The median number of viral load and CD4+ T-cell count measures contributed per participant was 29 (IQR 22-34).</s><s><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref> in which HIV negative donors were enrolled, counselled on HIV risk reduction and followed-up prospectively and how the nested case-control subset was accrued.</s><s>For the case control analysis of HIV acquisition, 154 women who acquired HIV were compared with 155 women who remained HIV negative through follow-up.</s><s>For cohort analyses of HIV course, 154 women who acquired HIV and were followed up for up to 120 months were studied.</s><s>Follow-up time and disposition as at 1 August 2014 (date of censorship), is shown in the lower panel for each donor where dot color denotes disposition (green: remains in follow-up, red: exited study as commenced cART or death, black:lost to follow-up)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical methods</head><p><s>Statistical analyses were performed according to an a priori statistical analysis plan (Additional file 1) with minor amendments made to update KIR haplotype definitions.</s><s>For comparisons between women who acquired HIV and those who did not, logistic regression models were employed.</s></p><p><s>To accommodate potential inter-and intra-patient sources of variation we used linear mixed-effects models to study potential correlates of HIV viral load and CD4+ T-cell count decline because of their flexibility in allowing for possible heterogeneity in population, and potential imbalance in the longitudinal data.</s><s>Graphical plotting of individual measures was performed using R software, and locally weighted scatterplot smoothing (LOWESS) was employed to derive aggregate curves.</s><s>Analyses were performed in R using the following packages 'lme4' , 'survival' , 'ggplot2' , 'rms' and 'LDheatmap'.</s><s>P-values presented are nominal (unadjusted) p-values unless otherwise stated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cohort accrual</head><p><s>Between May 2004 and March 2010, 1924 HIV negative women at risk for HIV acquisition were enrolled in one of three cohort studies in KwaZulu-Natal, South Africa and followed up to identify incident infection (Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>During a median of 16 months of active follow-up (IQR 7.8-23.7 months) with monthly or quarterly screening for HIV, 184 women acquired HIV (HIV incidence rate: 7.63 per 100 PY; 95 % CI 6.59-8.78).</s><s>Of these, 160 women (of whom 154 were KIR-genotyped) consented to inclusion in continued follow-up and were enrolled at a median of 42 (IQR 28-62) days post infection into the CAPRISA AI study.</s><s>As at August 2014, the median follow-up was 54 (IQR 31-69) months and at this point 8 were lost to follow up, 8 had died, 1 withdrew from the study, 101 commenced cART at a median of 50 (IQR 32-65) months after infection and 42 remain in follow-up.</s><s>For cohort analyses we excluded 15 individuals due to missing data, leaving 139 individuals with follow up data.</s><s>The cumulative follow-up time was 629.3 woman-years.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neither KIR nor HLA profiles are associated with HIV acquisition</head><p><s>To test whether KIR-HLA profiles are associated with risk of HIV acquisition we compared KIR gene content, and HLA alleles among 154 women (cases) who acquired HIV to 155 women (controls) who did not acquire infection during follow-up.</s><s>With this sample size we had 80 % power to detect predictors with odds ratio &lt;0.63 or &gt;1.6 at α = 5 % given the cohort HIV incidence of ~7 %.</s><s>The frequency of KIR genes, HLA alleles or groups, and KIR-HLA ligand pairs was not associated with HIV acquisition in logistic regression models (Table <ref type="table" target="#tab_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Presence of the KIR haplotype BB is associated with lower viral loads during HIV infection and higher CD4+ T-cell counts</head><p><s>To test whether KIR or HLA are associated with differences in the course of disease we used a linear mixed model approach to model post-infection viral loads accounting for differences in times of viral load or CD4+ Tcell count measurement and inter-participant variation amongst 139 women.</s></p><p><s>The presence of KIR haplotype BB was significantly associated with lower viral loads (overall effect: −0.44log 10 copies/ml, p = 0.03, Table <ref type="table" target="#tab_2">2</ref> and Fig. <ref type="figure">2a</ref>).</s><s>This observation was consistent regardless of the cohort from which these women were enrolled (Additional file 2: Figure <ref type="figure" target="#fig_0">S1</ref>).</s><s>Concordantly, CD4+ T-cell counts were higher in individuals with BB compared with AA/AB haplotypes (overall effect: +80 cells/μl, p = 0.04, Fig. <ref type="figure">2b</ref>).</s><s>Data beyond around 60 months of follow-up are sparse leading to overlapping confidence intervals thereafter.</s><s>Crosssectional analysis of viral loads supports this observation (Additional file 3: Figure <ref type="figure">S2</ref>).</s><s>Amongst 24 women for whom CD4 + T-cell counts prior to HIV acquisition were available, the counts did not differ according to haplotype (n AA = 6, n AB = 14 and n BB = 4; median AA = 914, median AB = 981 and median BB = 824 cells/μl, Kruskal-Wallis rank sum test χ 2 = 1.8, p = 0.4) and the time of enrolment following HIV acquisition did not significantly differ between groups.</s></p><p><s>Classical HLA class I alleles grouped by presence/absence of Bw4/Bw6 epitopes or C1/C2 groups were not, on their own, associated with course of viraemia but previously reported protective HLA alleles (B*13:02, B*27, B*57, B*58:01 or B*81:01) tended to be associated with lower viral loads (effect: −0.27 log 10 copies/ml p = 0.10), and harmful alleles (B*18:01, B*35 or B*58:02) with higher viral loads (effect: +0.25 log 10 copies/ml p = 0.06, Additional file 4: Figure <ref type="figure">S3</ref>).</s><s>Inclusion of HLA alleles in the model did not attenuate association between KIR and course of HIV viraemia.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Allelic state of KIR2DL2/KIR2DL3 may explain KIR genotype effects on HIV viral loads</head><p><s>Next, we examined whether the presence of specific KIR on the B haplotype may explain the observation above.</s><s>In contrast to previous reports, the absolute number of activating or inhibitory KIR-ligand pairs did not associate with HIV viraemia (data not shown).</s><s>However, the presence of KIR2DL2 was associated with reduced HIV viral loads through the first 3-4 years of HIV and conversely, the presence of one or two copies of KIR2DL3 was significantly associated with elevated HIV viral loads (+0.33 and +0.46 log 10 copies/ml respectively relative to KIR2DL2/KIR2DL2, p = 0.02).</s><s>The extensive linkage disequilibrium between KIR genes (Fig. <ref type="figure">2c</ref>), can be leveraged to further understand this observation.</s><s>Contrasting direction of effect between KIR2DL2 and KIR2DL3 and concordant protective effect of KIR2DS2 supports their involvement in HIV viral control because KIR2DL2 and KIR2DL3 segregate as alleles of the same locus and KIR2DL2 and KIR2DS2 are in moderate linkage disequilibrium.</s><s>Intriguingly, KIR2DL2/KIR2DL3 heterozygous individuals have viral loads that are similar to KIR2DL3/KIR2DL3 homozygous individuals suggesting that even one copy of KIR2DL3 is associated with elevated viraemia (Fig. <ref type="figure">2d</ref>).</s><s>A similar observation is noted when examining CD4+ T-cell counts (Fig. <ref type="figure">2b</ref>).</s><s>These data are consistent with the observation that BB haplotypes of KIR are associated with reduced viraemia as KIR2DL2 is a constituent of the B haplotype.</s></p><p><s>To assess whether KIR-ligand interactions may be involved we examined HIV viral loads according to gene content at the KIR2DL2/KIR2DL3 locus and their ligands: HLA alleles of the C1/C2 groups (Additional file 5: Table <ref type="table" target="#tab_1">S1</ref>).</s><s>Linear mixed models testing for an interaction between KIR2DL2/KIR2DL3 locus gene content and the number of HLA C1/C2 ligands did not provide evidence of statistical interaction.</s><s>Graphical examination of viral load measures and CD4+ T-cell counts support this interpretation (Additional file 6: Figure <ref type="figure">S4</ref>).</s><s>Although larger studies may reveal nuanced effects, given the observations here the association between KIR2DL2/ KIR2DL3 and HIV viraemia does not appear to be discernably modified by HLA C1/C2 ligands.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>KIR and HLA haplotypes have been associated with HIV disease outome, but little is known about their role in HIV acquisition.</s><s>Using a large cohort of prospectively enrolled women at risk for HIV, we did not observe evidence of association between KIR profiles and HIV-1 acquisition.</s><s>This finding is consistent with recent studies that suggest that genetic variation does not explain a substantial proportion in liability to acquire HIV-1 <ref type="bibr" target="#b32">[33,</ref><ref type="bibr" target="#b33">34]</ref>.</s><s>In contrast, we found that KIR genotype BB, which encodes KIR2DL2, was associated with lower HIV viraemia and higher CD4+  T-cell counts sustained over more than 5 years in a cohort of more than 130 prospectively followed South African women from a homogenous ethnic background.</s></p><p><s>Lack of association between KIR haplotype and HIV-1 acquisition observed here are in contrast to previous smaller studies linking higher activating:inhibitory KIR  Fig. <ref type="figure">2</ref> KIR haplotype BB is associated with a lower VL and b higher CD4+ T-cell counts in primary HIV infection.</s><s>c The linkage-disequilibrium between KIR genes.</s><s>d KIR2DL2 is associated with lower viral loads whilst KIR2DL3 (homozygous or heterozygous) is associated with relatively higher viral loads.</s></p><formula xml:id="formula_0">K I R 3 D L 3 K I R 2 D S 2 K I R 2 D L 2 K I R 2 D L 3 K I R 2 D L 5 K I R 2 D S 3 K I R 2 D S 5 K I R 2 D P 1 K I R 2 D L 1 K I R 2 D L 4 K I R 3 D L 1 K I R 3 D S 1 K I R 2 D S 1 K I R 2 D S 4 K I R 3 D L 2</formula><p><s>Each plot shows the individual viral load or CD4 count measure as well as a LOWESS -smoothed curve fitted to the data as well as the 95 % confidence interval for the curve (grey shading adjacent to coloured lines)</s></p><p><s>receptor repertoires, and the presence of KIR3DS1 in particular, and genotype AB, with reduced HIV acquisition <ref type="bibr" target="#b9">[10]</ref>.</s><s>The KIR3DS1 gene is infrequent in the population under study, which is typical for populations of African descent <ref type="bibr" target="#b34">[35]</ref>.</s><s>Our study, despite being larger than previous studies, was powered to identify covariates with unadjusted odds ratio &lt;0.63 or &gt;1.6, hence we may commit type 2 error if true effect sizes exist and are smaller.</s><s>Although not feasible here, a more robust strategy would have been a prospective cohort analysis.</s></p><p><s>The association between KIR and HIV disease course is in agreement with immunogenetic <ref type="bibr" target="#b4">[5]</ref> and functional studies <ref type="bibr" target="#b35">[36]</ref> as well as recent evidence that NK cell function is a feature of HIV-1 control in patients with poor CD8+ T-cell responses <ref type="bibr" target="#b36">[37]</ref>.</s><s>Similarly, in HCV and HTLV-1 infection KIR2DL2 modifies HLA mediated effects on disease and is thereby implicated in protective responses <ref type="bibr" target="#b19">[20]</ref>.</s><s>However, our data are in contrast with observations reported by Khakoo et al. on Hepatitis C infection, where KIR2DL3 homozygous individuals had superior resolution <ref type="bibr" target="#b37">[38]</ref>.</s><s>These different outcomes may be explained by differences in pathogenesis between HCV and HIV-1.</s><s>Our findings are also in contrast to a previous report of lower CD4+ T-cell counts in HIV infected KIR haplotype B carriers <ref type="bibr" target="#b38">[39]</ref>.</s><s>However, this apparent discrepancy may be due to cross-sectional sampling in Jennes et al. <ref type="bibr" target="#b38">[39]</ref> leading to a frailty bias in selection of participants and consequent reversal of direction of effect as was recently observed in a separate study <ref type="bibr" target="#b32">[33]</ref>.</s><s>Gaudieri et al. also reported that carriage of either of the haplotype B genes KIR2DS2 or KIR2DL2 was associated with more rapid CD4+ T-cell decline, but they did not specifically assess the combined haplotype <ref type="bibr" target="#b39">[40]</ref>.</s><s>Nevertheless, these findings suggest the potential for population heterogeneity in effect and highlight the challenges in confidently delineating which KIR gene contributes to the haplotype effect.</s></p><p><s>Several underlying mechanisms may be involved in KIR2DL2 mediated enhancement of HIV control, or reciprocally of KIR2DL3 impairment.</s><s>Firstly, the presence of KIR2DL2 associated footprints in virus sequenced from KIR2DL2+ donors supports a model in which KIR2DL2 may bind HIV-derived viral peptides presented by HLA-C <ref type="bibr" target="#b16">[17]</ref>.</s><s>In vitro studies using viral peptide variants suggest that selected viral peptides enhance KIR2DL2 binding, resulting in NK cell inhibition and diminished degranulation, hence affording the virus a selection advantage <ref type="bibr" target="#b40">[41]</ref>.</s><s>This may explain why the beneficial effect of KIR2DL2 may be lost later in infection.</s><s>Whilst differing by only a few amino acids, KIR2DL2 has been reported to have higher affinity for HLA-CI than KIR2DL3, and KIR2DL2/ 2DL3 differ in their sensitivity to peptide bound in the HLA C groove offering a further potential explanation for how subtle differences may explain the divergent effects of KIR2DL2/L3 <ref type="bibr" target="#b41">[42]</ref>.</s><s>Although Korner et al. <ref type="bibr" target="#b14">[15]</ref>, show that KIR2DL2+ NK cells are functionally more potent in the presence of HLA-C1/C1, because KIR2DL2 mediates inhibitory signals following binding to HLA-C molecules of both HLA-C1 or HLA-C2, the absence of an interaction between KIR2DL2 and HLA-C1/C2 group in our study is compatible with this model <ref type="bibr" target="#b42">[43]</ref>.</s><s>The linkage disequilibrium that we found between KIR2DL2 and KIR2DS2 was consistent with previous studies <ref type="bibr" target="#b43">[44]</ref> and implies that a role for KIR2DS2 cannot be excluded.</s><s>An alternative mechanism is suggested by Schonberg et al. <ref type="bibr" target="#b42">[43]</ref> who report that due to differences in timing of KIR2DL2 and KIR2DL1 expression, the presence of KIR2DL2 may affect ligand-instructed NK cell education during development.</s><s>Finally, KIR2DL2 may act indirectly to alter T-cell recognition of virally infected cells as described in HTLV-1 and HCV infection <ref type="bibr" target="#b19">[20]</ref>.</s></p><p><s>Blockade of inhibitory KIR interaction with HLA-C has been pursued as therapeutic strategy in malignancy and viral infection <ref type="bibr" target="#b44">[45]</ref>.</s><s>An antibody that blocks interaction of KIR2DL1/L2/L3/S1/S2 (1-7 F9) with HLA-C, was shown to enhance degranulation of NK cells from HIV infected donors cocultured with target cells in vitro <ref type="bibr" target="#b45">[46]</ref>.</s><s>The enhancement in NK cell degranulation observed with 1-7 F9 was higher amongst NK cells from donors with KIR haplotype B in congruence with our observations.</s><s>However, precise delineation of the role of KIR2DL2, KIR2DL3 and KIR2DS2 is difficult.</s><s>This approach has been further developed in acute myeloid leukaemia (AML), multiple myeloma (MM) and lymphoma models <ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref>.</s><s>A humanised version (lirilumab) was shown to be safe <ref type="bibr" target="#b49">[50]</ref> in humans and is currently in clinical trials for treatment of AML (NCT01687387), MM (NCT02252263, NCT01592370), lymphoma (NCT01592 370) and some solid organ tumours (NCT01750580, NC T01714739).</s><s>We speculate that similar approaches may be beneficial in HIV.</s></p><p><s>In spite of having a pre-determined data analysis plan and consistent viral load and CD4+ T-cell measures across both sub-cohorts, we cannot exclude that this finding is a false positive due to multiple comparisons.</s><s>Larger studies, that limit analyses to replication of this finding, are required.</s><s>In addition, this study has other noteworthy limitations.</s><s>Firstly, it is limited by the lack of resolution of specific KIR alleles and copy number.</s><s>Secondly, in the case control analysis we were unable to account for the transmitting partners KIR status constraining our ability to confirm previous reports of KIR2DS4*001 carriage in the transmitting partner being linked to enhanced transmission risk <ref type="bibr" target="#b50">[51]</ref>.</s><s>Thirdly, the limited sample size prohibited subgroup analyses, for example, of HLA C1/C2 ligand interactions.</s><s>Finally, we were unable to link these clinical observations with previously reported flow-cytometry based measures of NK cell function <ref type="bibr" target="#b22">[23]</ref> due to the absence of KIR2DL2/L3 specific antibodies used in our previous work.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p><s>Fig.1Cohort accrual diagram and study design.</s><s>The figure shows the three parent studies<ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref> in which HIV negative donors were enrolled, counselled on HIV risk reduction and followed-up prospectively and how the nested case-control subset was accrued.</s><s>For the case control analysis of HIV acquisition, 154 women who acquired HIV were compared with 155 women who remained HIV negative through follow-up.</s><s>For cohort analyses of HIV course, 154 women who acquired HIV and were followed up for up to 120 months were studied.</s><s>Follow-up time and disposition as at 1 August 2014 (date of censorship), is shown in the lower panel for each donor where dot color denotes disposition (green: remains in follow-up, red: exited study as commenced cART or death, black:lost to follow-up)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Results of logistic regression model of KIR/HLA and HIV acquisition</s></p></div></figDesc><table><row><cell></cell><cell cols="2">HIV-(n = 155)</cell><cell></cell><cell cols="2">HIV+ (n = 154)</cell><cell></cell><cell>p a</cell><cell>OR a</cell><cell>95 % CI a</cell></row><row><cell></cell><cell>-</cell><cell>+</cell><cell>+ %</cell><cell>-</cell><cell>+</cell><cell>+ %</cell><cell></cell><cell></cell><cell></cell></row><row><cell>KIR loci</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>KIR2DL1</cell><cell>4</cell><cell>151</cell><cell>97.4 %</cell><cell>0</cell><cell>154</cell><cell>100.0 %</cell><cell>0.98</cell><cell>-</cell><cell>-</cell></row><row><cell>KIR2DL2</cell><cell>45</cell><cell>110</cell><cell>71.0 %</cell><cell>46</cell><cell>107</cell><cell>69.9 %</cell><cell>0.89</cell><cell>1.04</cell><cell>0.63-1.71</cell></row><row><cell>KIR2DL2/KIR2DL2</cell><cell></cell><cell>39</cell><cell>25.5 %</cell><cell></cell><cell>35</cell><cell>22.9 %</cell><cell></cell><cell></cell><cell></cell></row><row><cell>KIR2DL2/KIR2DL3</cell><cell></cell><cell>70</cell><cell>45.8 %</cell><cell></cell><cell>72</cell><cell>47.1 %</cell><cell>0.63</cell><cell>1.15</cell><cell>0.43-2.05</cell></row><row><cell>KIR2DL3/KIR2DL3</cell><cell></cell><cell>44</cell><cell>28.8 %</cell><cell></cell><cell>46</cell><cell>30.1 %</cell><cell>0.83</cell><cell>1.07</cell><cell>0.32-2.00</cell></row><row><cell>KIR2DL3</cell><cell>40</cell><cell>114</cell><cell>74.0 %</cell><cell>35</cell><cell>118</cell><cell>77.1 %</cell><cell>0.61</cell><cell>1.15</cell><cell>0.68-1.94</cell></row><row><cell>KIR2DL4</cell><cell>3</cell><cell>152</cell><cell>98.1 %</cell><cell>0</cell><cell>154</cell><cell>100.0 %</cell><cell>0.98</cell><cell>-</cell><cell>-</cell></row><row><cell>KIR2DL5</cell><cell>44</cell><cell>111</cell><cell>71.6 %</cell><cell>56</cell><cell>98</cell><cell>63.6 %</cell><cell>0.18</cell><cell>0.72</cell><cell>0.44-1.16</cell></row><row><cell>KIR3DL1</cell><cell>0</cell><cell>155</cell><cell>100.0 %</cell><cell>0</cell><cell>154</cell><cell>100.0 %</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>KIR3DL1/KIR3DL1</cell><cell></cell><cell>145</cell><cell>94.8 %</cell><cell></cell><cell>141</cell><cell>92.2 %</cell><cell></cell><cell></cell><cell></cell></row><row><cell>KIR3DL1/KIR3DS1</cell><cell></cell><cell>8</cell><cell>5.2 %</cell><cell></cell><cell>12</cell><cell>7.8 %</cell><cell>0.27</cell><cell>1.69</cell><cell>0.62-4.04</cell></row><row><cell>KIR3DS1/KIR3DS1</cell><cell></cell><cell>0</cell><cell>0.0 %</cell><cell></cell><cell>0</cell><cell>0.0 %</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>KIR3DS1</cell><cell>145</cell><cell>8</cell><cell>5.2 %</cell><cell>141</cell><cell>12</cell><cell>7.8 %</cell><cell>0.27</cell><cell>1.69</cell><cell>0.67-4.45</cell></row><row><cell>KIR3DL2</cell><cell>0</cell><cell>155</cell><cell>100.0 %</cell><cell>0</cell><cell>154</cell><cell>100.0 %</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>KIR3DL3</cell><cell>2</cell><cell>153</cell><cell>98.7 %</cell><cell>0</cell><cell>154</cell><cell>100.0 %</cell><cell>0.98</cell><cell>-</cell><cell>-</cell></row><row><cell>KIR2DS1</cell><cell>135</cell><cell>18</cell><cell>11.8 %</cell><cell>130</cell><cell>24</cell><cell>15.6 %</cell><cell>0.23</cell><cell>1.51</cell><cell>0.78-2.96</cell></row><row><cell>KIR2DS2</cell><cell>63</cell><cell>92</cell><cell>59.4 %</cell><cell>60</cell><cell>94</cell><cell>61.0 %</cell><cell>0.56</cell><cell>1.15</cell><cell>0.72-1.83</cell></row><row><cell>KIR2DS3</cell><cell>104</cell><cell>51</cell><cell>32.9 %</cell><cell>111</cell><cell>43</cell><cell>27.9 %</cell><cell>0.43</cell><cell>0.82</cell><cell>0.50-1.34</cell></row><row><cell>KIR2DS3/KIR2DS3</cell><cell></cell><cell>29</cell><cell>25.9 %</cell><cell></cell><cell>24</cell><cell>24.2 %</cell><cell></cell><cell></cell><cell></cell></row><row><cell>KIR2DS3/KIR2DS5</cell><cell></cell><cell>22</cell><cell>19.6 %</cell><cell></cell><cell>19</cell><cell>19.2 %</cell><cell>0.77</cell><cell>1.13</cell><cell>0.49-2.60</cell></row><row><cell>KIR2DS5/KIR2DS5</cell><cell></cell><cell>61</cell><cell>54.5 %</cell><cell></cell><cell>56</cell><cell>56.6 %</cell><cell>0.77</cell><cell>1.11</cell><cell>0.57-2.14</cell></row><row><cell>KIR2DS5</cell><cell>72</cell><cell>83</cell><cell>53.5 %</cell><cell>79</cell><cell>75</cell><cell>48.7 %</cell><cell>0.47</cell><cell>0.85</cell><cell>0.54-1.33</cell></row><row><cell>KIR2DS4 b</cell><cell>2</cell><cell>153</cell><cell>98.7 %</cell><cell>1</cell><cell>153</cell><cell>99.4 %</cell><cell>0.63</cell><cell>1.80</cell><cell>0.17-39.03</cell></row><row><cell>197/.</cell><cell></cell><cell>23</cell><cell>20.2 %</cell><cell></cell><cell>11</cell><cell>19.0 %</cell><cell></cell><cell></cell><cell></cell></row><row><cell>197/219</cell><cell></cell><cell>31</cell><cell>27.2 %</cell><cell></cell><cell>25</cell><cell>43.1 %</cell><cell>0.25</cell><cell>1.57</cell><cell>0.70-4.21</cell></row><row><cell>./219</cell><cell></cell><cell>60</cell><cell>52.6 %</cell><cell></cell><cell>22</cell><cell>37.9 %</cell><cell>0.55</cell><cell>1.56</cell><cell>0.32-1.87</cell></row><row><cell>KIR Haplotype</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Bx</cell><cell>33</cell><cell>121</cell><cell>78.6 %</cell><cell>40</cell><cell>113</cell><cell>73.9 %</cell><cell>0.45</cell><cell>0.81</cell><cell>0.48-1.39</cell></row><row><cell>AA</cell><cell></cell><cell>33</cell><cell>21.4 %</cell><cell></cell><cell>40</cell><cell>26.1 %</cell><cell></cell><cell></cell><cell></cell></row><row><cell>AB</cell><cell></cell><cell>77</cell><cell>50.0 %</cell><cell></cell><cell>78</cell><cell>51.0 %</cell><cell>0.65</cell><cell>0.88</cell><cell>0.50-1.55</cell></row><row><cell>BB</cell><cell></cell><cell>44</cell><cell>28.6 %</cell><cell></cell><cell>35</cell><cell>22.9 %</cell><cell>0.27</cell><cell>0.70</cell><cell>0.36-1.33</cell></row><row><cell>HLA Groups</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Protective B alleles</cell><cell>122</cell><cell>33</cell><cell>21.3 %</cell><cell>128</cell><cell>26</cell><cell>16.9 %</cell><cell>0.33</cell><cell>0.75</cell><cell>0.42-1.33</cell></row><row><cell>Harmful B alleles</cell><cell>108</cell><cell>47</cell><cell>30.3 %</cell><cell>104</cell><cell>50</cell><cell>32.5 %</cell><cell>0.80</cell><cell>1.07</cell><cell>0.66-1.73</cell></row><row><cell>Bw4</cell><cell>109</cell><cell>46</cell><cell>29.7 %</cell><cell>103</cell><cell>51</cell><cell>33.1 %</cell><cell>0.50</cell><cell>1.18</cell><cell>0.73-1.92</cell></row><row><cell>Bw6</cell><cell>75</cell><cell>80</cell><cell>51.6 %</cell><cell>77</cell><cell>77</cell><cell>50.0 %</cell><cell>0.70</cell><cell>0.92</cell><cell>0.58-1.44</cell></row><row><cell>C1/C1</cell><cell></cell><cell>21</cell><cell>13.5 %</cell><cell></cell><cell>18</cell><cell>11.7 %</cell><cell></cell><cell></cell><cell></cell></row><row><cell>C1/C2</cell><cell></cell><cell>68</cell><cell>43.9 %</cell><cell></cell><cell>73</cell><cell>47.4 %</cell><cell>0.76</cell><cell>1.35</cell><cell>0.65-2.81</cell></row><row><cell>C2/C2</cell><cell></cell><cell>66</cell><cell>42.6 %</cell><cell></cell><cell>63</cell><cell>40.9 %</cell><cell>0.70</cell><cell>1.18</cell><cell>0.56-2.52</cell></row><row><cell>KIR/HLA Ligand Pair</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>KIR2DL1_C2</cell><cell>33</cell><cell>122</cell><cell>78.7 %</cell><cell>25</cell><cell>129</cell><cell>83.8 %</cell><cell>0.22</cell><cell>1.44</cell><cell>0.81-2.59</cell></row><row><cell>KIR2DS1_C2</cell><cell>140</cell><cell>15</cell><cell>9.7 %</cell><cell>132</cell><cell>22</cell><cell>14.3 %</cell><cell>0.15</cell><cell>1.68</cell><cell>0.84-3.46</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1</head><label>1</label><figDesc><div><p><s>Results of logistic regression model of KIR/HLA and HIV acquisition (Continued)</s></p></div></figDesc><table><row><cell>KIR2DL2_C1</cell><cell>90</cell><cell>65</cell><cell>41.9 %</cell><cell>92</cell><cell>62</cell><cell>40.3 %</cell><cell>0.77</cell><cell>0.93</cell><cell>0.59-1.47</cell></row><row><cell>KIR2DL3_C1</cell><cell>94</cell><cell>61</cell><cell>39.4 %</cell><cell>85</cell><cell>69</cell><cell>44.8 %</cell><cell>0.43</cell><cell>1.20</cell><cell>0.76-1.90</cell></row><row><cell>KIR3DL1_Bw4</cell><cell>109</cell><cell>46</cell><cell>29.7 %</cell><cell>103</cell><cell>51</cell><cell>33.1 %</cell><cell>0.50</cell><cell>1.18</cell><cell>0.73-1.92</cell></row><row><cell>KIR3DS1_Bw4</cell><cell>150</cell><cell>5</cell><cell>3.2 %</cell><cell>148</cell><cell>6</cell><cell>3.9 %</cell><cell>0.68</cell><cell>1.29</cell><cell>0.38-4.59</cell></row><row><cell>KIR2DS4_Cw04</cell><cell>128</cell><cell>27</cell><cell>17.4 %</cell><cell>128</cell><cell>26</cell><cell>16.9 %</cell><cell>0.86</cell><cell>1.04</cell><cell>0.57-1.91</cell></row><row><cell>KIR3DL2_A3A11</cell><cell>134</cell><cell>21</cell><cell>13.5 %</cell><cell>133</cell><cell>21</cell><cell>13.6 %</cell><cell>0.98</cell><cell>1.01</cell><cell>0.52-1.95</cell></row><row><cell cols="10">Previous Presentations: A part of these data was presented at the International Immunogenetics and HLA Workshop 2012. Liverpool, UK, 28 May-3 June 2012</cell></row><row><cell cols="2">a (adjusted for tenofovir gel use)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="10">b For a subset (172/309, 56 %) KIR2DS4 alleles were genotyped where 197 denotes the common deletion variant of KIR2DS4 that has a 22 bp deletion in exon 5</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2</head><label>2</label><figDesc><div><p><s>linear mixed-effects model results for association between KIR/HLA and HIV viraemia in 139 women with incident HIV infection followed up for up to 10 years post infection</s></p></div></figDesc><table><row><cell></cell><cell>VL Intercept</cell><cell>Effect</cell><cell>SE</cell><cell>nominal</cell></row><row><cell></cell><cell>(log 10 /ml)</cell><cell>(log 10 /ml)</cell><cell></cell><cell>p-value</cell></row><row><cell>Fixed effects</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Haplotype</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>AA</cell><cell>4.52</cell><cell>Ref</cell><cell>0.15</cell><cell>0.03</cell></row><row><cell>AB</cell><cell></cell><cell>−0.08</cell><cell>0.15</cell><cell></cell></row><row><cell>BB</cell><cell></cell><cell>−0.44</cell><cell>0.18</cell><cell></cell></row><row><cell>KIR loci</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>KIR2DL2/KIR2DL2</cell><cell>4.08</cell><cell>Ref</cell><cell>0.15</cell><cell>0.02</cell></row><row><cell>KIR2DL2/KIR2DL3</cell><cell></cell><cell>0.33</cell><cell>0.16</cell><cell></cell></row><row><cell>KIR2DL3/KIR2DL3</cell><cell></cell><cell>0.46</cell><cell>0.17</cell><cell></cell></row><row><cell>KIR2DL5</cell><cell>4.43</cell><cell>−0.13</cell><cell>0.13</cell><cell>0.32</cell></row><row><cell>KIR3DL1/KIR3DL1</cell><cell>4.33</cell><cell>Ref</cell><cell>0.10</cell><cell>0.84</cell></row><row><cell>KIR3DL1/KIR3DS1</cell><cell></cell><cell>−0.05</cell><cell>0.24</cell><cell></cell></row><row><cell>KIR3DS1/KIR3DS1</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell></cell></row><row><cell>KIR2DS1</cell><cell>4.36</cell><cell>−0.13</cell><cell>0.19</cell><cell>0.47</cell></row><row><cell>KIR2DS2</cell><cell>4.53</cell><cell>−0.28</cell><cell>0.13</cell><cell>0.03</cell></row><row><cell>KIR2DS3/KIR2DS3</cell><cell>4.03</cell><cell>Ref</cell><cell>0.19</cell><cell>0.14</cell></row><row><cell>KIR2DS3/KIR2DS5</cell><cell></cell><cell>0.01</cell><cell>0.25</cell><cell></cell></row><row><cell>KIR2DS5/KIR2DS5</cell><cell></cell><cell>0.33</cell><cell>0.20</cell><cell></cell></row><row><cell>KIR2DS4</cell><cell>4.43</cell><cell>−0.08</cell><cell>0.77</cell><cell>0.91</cell></row><row><cell>HLA groups</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Protective HLA-B alleles</cell><cell>4.38</cell><cell>−0.27</cell><cell>0.17</cell><cell>0.10</cell></row><row><cell>Harmful HLA-B alleles</cell><cell>4.26</cell><cell>0.25</cell><cell>0.13</cell><cell>0.06</cell></row><row><cell>Bw4</cell><cell>4.33</cell><cell>0.07</cell><cell>0.14</cell><cell>0.63</cell></row><row><cell>Bw6</cell><cell>4.39</cell><cell>−0.08</cell><cell>0.13</cell><cell>0.52</cell></row><row><cell>Number of C1 epitopes</cell><cell>4.40</cell><cell>−0.08</cell><cell>0.09</cell><cell>0.40</cell></row><row><cell>Number of C2 epitopes</cell><cell>4.25</cell><cell>0.07</cell><cell>0.09</cell><cell>0.43</cell></row><row><cell>Random Effects</cell><cell></cell><cell>Variance</cell><cell>SD</cell><cell></cell></row><row><cell>Weeks postinfection</cell><cell>(Intercept)</cell><cell>0.02</cell><cell>0.12</cell><cell></cell></row><row><cell>X002PID</cell><cell>(Intercept)</cell><cell>0.61</cell><cell>0.78</cell><cell></cell></row><row><cell>Residual</cell><cell></cell><cell>0.31</cell><cell>0.55</cell><cell></cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>We thank the participants of the CAPRISA study cohorts; women who are dedicated and committed to improving their and their peers' health and who donate samples to make this research possible.</s><s>We thank Mary Carrington for helpful advice in preparation of this manuscript.</s><s>Author details 1 Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. <ref type="bibr" target="#b1">2</ref> Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK. <ref type="bibr" target="#b2">3</ref> HIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, South Africa. <ref type="bibr" target="#b3">4</ref></s><s>National Institute of Communicable Diseases, Sandringham, South Africa. <ref type="bibr" target="#b4">5</ref></s><s>University of the Witwatersrand, Johannesburg, South Africa. <ref type="bibr" target="#b5">6</ref></s><s>University of Cape Town, Cape Town, South Africa. <ref type="bibr" target="#b6">7</ref></s><s>City University of New York -Medgar Evers College, New York, USA. <ref type="bibr" target="#b7">8</ref> Ragon Institute of MGH, MIT and Harvard University, Boston, USA. <ref type="bibr" target="#b8">9</ref> Mailman School of Public Health, Columbia University, New York, USA. <ref type="bibr" target="#b9">10</ref> Leibniz Institute for Experimental Virology, Heinrich Pette Institute, Hamburg, Germany. 11</s><s>KwaZulu-Natal Research Institute for Tuberculosis and HIV, University of KwaZulu-Natal, Durban, South Africa. <ref type="bibr" target="#b11">12</ref></s><s>Max Planck Institute for Infection Biology, Chariteplatz, D-10117 Berlin, Germany. <ref type="bibr" target="#b12">13</ref></s><s>Division of Virology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>Our data suggest that KIR2DL2 on the B KIR haplotype may mediate measurable control of HIV viraemia and underlies a protective effect through the early years of chronic HIV infection.</s><s>Larger studies are required to confirm this finding and establish its generalizability.</s><s>These data also support exploration of using KIR-blocking approaches to manipulate NK cell function in HIV infection.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional files</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p><s>The authors have no relevant conflict of interests to report.</s></p><p><s>Authors' contributions SSAK, QAK, AK, NG, SS and KM were involved in cohort accrual and clinical follow up.</s><s>VN, DdAR, HH, CG, and RM performed the KIR and HLA typing.</s><s>VN, LW, DC, MA, AVSH, WHC, SSAK, and TN led and performed analyses and all authors read and commented on the manuscript.</s><s>All authors read and approved the final manuscript.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The &apos;immunologic advantage&apos; of HIV-exposed seronegative individuals</title>
		<author>
			<persName><forename type="first">M</forename><surname>Miyazawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lopalco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mazzotta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lo</forename><surname>Caputo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Veas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Clerici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aids</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="161" to="175" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Host genetics of HIV acquisition and viral control</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Shea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Shianna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Carrington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Goldstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Med</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="203" to="217" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Unravelling the mechanisms of durable control of HIV-1</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">G</forename><surname>Yu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="487" to="498" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Influence of HLA-C expression level on HIV control</title>
		<author>
			<persName><forename type="first">R</forename><surname>Apps</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Qi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Carlson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Thomas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">340</biblScope>
			<biblScope unit="issue">6128</biblScope>
			<biblScope unit="page" from="87" to="91" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Detels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Goedert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="429" to="434" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">A whole-genome association study of major determinants for host control of HIV-1</title>
		<author>
			<persName><forename type="first">J</forename><surname>Fellay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Shianna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Colombo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ledergerber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">317</biblScope>
			<biblScope unit="issue">5840</biblScope>
			<biblScope unit="page" from="944" to="947" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Overview of the killer cell immunoglobulin-like receptor system</title>
		<author>
			<persName><forename type="first">R</forename><surname>Rajalingam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Methods Mol Biol</title>
		<imprint>
			<biblScope unit="volume">882</biblScope>
			<biblScope unit="page" from="391" to="414" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The HLA system. First of two parts</title>
		<author>
			<persName><forename type="first">J</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="702" to="709" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals</title>
		<author>
			<persName><forename type="first">S</forename><surname>Boulet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sharafi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Simic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bruneau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Routy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Tsoukas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aids</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="595" to="599" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands</title>
		<author>
			<persName><forename type="first">W</forename><surname>Jennes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Verheyden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Demanet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Adje-Toure</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Vuylsteke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Nkengasong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">177</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="6588" to="6592" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">KIR-HLA and maternal-infant HIV-1 transmission in sub-Saharan Africa</title>
		<author>
			<persName><forename type="first">M</forename><surname>Paximadis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Minevich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Winchester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Schramm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Sherman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">e16541</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ravet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Scott-Algara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bonnet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Nguyen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="4296" to="4305" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users</title>
		<author>
			<persName><forename type="first">D</forename><surname>Scott-Algara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">X</forename><surname>Truong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Versmisse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>David</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">T</forename><surname>Luong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">V</forename><surname>Nguyen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">171</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="5663" to="5667" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Evolution of innate and adaptive effector cell functions during acute HIV-1 infection</title>
		<author>
			<persName><forename type="first">G</forename><surname>Alter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Teigen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ahern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Streeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Meier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Rosenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">195</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1452" to="1460" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Increased frequency and function of KIR2DL1-3 NK cells in primary HIV-1 infection are determined by HLA-C group haplotypes</title>
		<author>
			<persName><forename type="first">C</forename><surname>Korner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Granoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Amero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Sirignano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Vaidya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jost</surname></persName>
		</author>
		<idno type="DOI">10.1002/eji.201444751</idno>
	</analytic>
	<monogr>
		<title level="j">Eur J Immunol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2938" to="2948" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C</title>
		<author>
			<persName><forename type="first">R</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Apps</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Qi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Male</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>O'huigin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1290" to="1294" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">HIV-1 adaptation to NK-cell-mediated immune pressure</title>
		<author>
			<persName><forename type="first">G</forename><surname>Alter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Heckerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schneidewind</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fadda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Kadie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Carlson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">476</biblScope>
			<biblScope unit="issue">7358</biblScope>
			<biblScope unit="page" from="96" to="100" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Expression of leukocyte immunoglobulin-like receptors and natural killer receptors on virus-specific CD8+ T cells during the evolution of Epstein-Barr virus-specific immune responses in vivo</title>
		<author>
			<persName><forename type="first">K</forename><surname>Poon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Montamat-Sicotte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Cumberbatch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Mcmichael</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Callan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Viral Immunol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="513" to="522" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Functional analysis of killer Ig-like receptor-expressing cytomegalovirus-specific CD8+ T cells</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Van Der Veken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Diez</forename><surname>Campelo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Der Hoorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Hagedoorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Van Egmond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Van Bergen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">182</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="92" to="101" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">KIR2DL2 enhances protective and detrimental HLA class I-mediated immunity in chronic viral infection</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Seich Al Basatena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Macnamara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Vine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Thio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Astemborski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Usuku</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS pathogens</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">e1002270</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Ligand-independent exhaustion of killer immunoglobulin-like receptor-positive CD8+ T cells in human immunodeficiency virus type 1 infection</title>
		<author>
			<persName><forename type="first">G</forename><surname>Alter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rihn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Streeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Teigen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Piechocka-Trocha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Moss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Virol</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="9668" to="9677" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Innate Immune Activation Enhances HIV Acquisition in Women, Diminishing the Effectiveness of Tenofovir Microbicide Gel</title>
		<author>
			<persName><forename type="first">V</forename><surname>Naranbhai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Abdool</forename><surname>Karim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Altfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Samsunder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Durgiah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sibeko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">206</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="993" to="1001" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Natural killer cell function in women at high risk for HIV acquisition: insights from a microbicide trial</title>
		<author>
			<persName><forename type="first">V</forename><surname>Naranbhai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Altfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Abdool</forename><surname>Karim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Ndung'u</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Abdool</forename><surname>Karim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Carr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aids</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="1745" to="1753" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Changes in Natural Killer cell activation and function during primary HIV-1 Infection</title>
		<author>
			<persName><forename type="first">V</forename><surname>Naranbhai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Altfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Karim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ndung'u</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">A</forename><surname>Karim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Carr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">e53251</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">HIV Disease Progression in Seroconvertors from the CAPRISA 004 Tenofovir Gel Pre-exposure Prophylaxis Trial</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Garrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Naicker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Naranbhai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sibeko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Samsunder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Acquir Immune Defic Syndr</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="55" to="61" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Rapid Disease Progression in HIV-1 Subtype C-Infected South African Women</title>
		<author>
			<persName><forename type="first">K</forename><surname>Mlisana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Garrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Mckinnon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Van Loggerenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Passmore</surname></persName>
		</author>
		<idno type="DOI">10.1093/cid/ciu573</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1322" to="1331" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women</title>
		<author>
			<persName><forename type="first">Abdool</forename><surname>Karim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Abdool</forename><surname>Karim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Frohlich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Grobler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Baxter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mansoor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">329</biblScope>
			<biblScope unit="issue">5996</biblScope>
			<biblScope unit="page" from="1168" to="1174" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">HIV incidence in young girls in KwaZulu-Natal, South Africa-public health imperative for their inclusion in HIV biomedical intervention trials</title>
		<author>
			<persName><forename type="first">Abdool</forename><surname>Karim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Kharsany</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Frohlich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mlotshwa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Madlala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AIDS Behav</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1870" to="1876" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study</title>
		<author>
			<persName><forename type="first">F</forename><surname>Van Loggerenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mlisana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Auld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Gray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">e1954</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Risk factors for HIV acquisition in high risk women in a generalised epidemic setting</title>
		<author>
			<persName><forename type="first">N</forename><surname>Naicker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Kharsany</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Van Loggerenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mlisana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Garrett</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10461-015-1002-5</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS Behav</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1305" to="1316" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women</title>
		<author>
			<persName><forename type="first">Abdool</forename><surname>Karim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Abdool</forename><surname>Karim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Frohlich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Grobler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Baxter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mansoor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">329</biblScope>
			<biblScope unit="issue">5996</biblScope>
			<biblScope unit="page" from="1168" to="1174" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Killer-cell immunoglobulin-like receptor genotyping and HLA killer-cell immunoglobulin-like receptor-ligand identification by real-time polymerase chain reaction</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Loubser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>De Assis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Naranbhai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Carr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Paximadis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tissue Antigens</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="185" to="194" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Mclaren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Coulonges</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ripke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Van Den Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Buchbinder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Carrington</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Pathog</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">e1003515</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Mclaren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dorrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Shianna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stemke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pelak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Mol Genet</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1903" to="1910" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Distribution of natural killer cell immunoglobulin-like receptor sequences in three ethnic groups</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Norman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Stephens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Verity</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Chandanayingyong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Vaughan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunogenetics</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">3-4</biblScope>
			<biblScope unit="page" from="195" to="205" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes</title>
		<author>
			<persName><forename type="first">G</forename><surname>Alter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Teigen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Carr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Suscovich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schneidewind</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">204</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3027" to="3036" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Post-Treatment Controllers Have Particular NK Cells With High Anti-HIV Capacity: VISCONTI Study</title>
		<author>
			<persName><forename type="first">D</forename><surname>Scott-Algara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Didier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Arnold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Cummings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sáez-Cirión</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Boufassa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">CROI 2015</title>
				<meeting><address><addrLine>Seattle, Washington</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus</title>
		<author>
			<persName><forename type="first">S</forename><surname>Knapp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Warshow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hegazy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Brackenbury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">N</forename><surname>Guha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fowell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hepatology</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1168" to="1175" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Low CD4+ T cell counts among African HIV-1 infected subjects with group B KIR haplotypes in the absence of specific inhibitory KIR ligands</title>
		<author>
			<persName><forename type="first">W</forename><surname>Jennes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Verheyden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Demanet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Menten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Vuylsteke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Nkengasong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">e17043</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Associations between KIR epitope combinations expressed by HLA-B/-C haplotypes found in an HIV-1 infected study population may influence NK mediated immune responses</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gaudieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nolan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mckinnon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Witt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mallal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">T</forename><surname>Christiansen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Immunol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="557" to="560" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">HLA-Cw*0102-restricted HIV-1 p24 epitope variants can modulate the binding of the inhibitory KIR2DL2 receptor and primary NK cell function</title>
		<author>
			<persName><forename type="first">L</forename><surname>Fadda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Korner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Van Teijlingen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Piechocka-Trocha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Carrington</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Pathog</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">e1002805</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Peptide selectivity discriminates NK cells from KIR2DL2-and KIR2DL3-positive individuals</title>
		<author>
			<persName><forename type="first">S</forename><surname>Cassidy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mukherjee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Myint</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mbiribindi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>North</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Traherne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Immunol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="492" to="500" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition</title>
		<author>
			<persName><forename type="first">K</forename><surname>Schonberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sribar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Enczmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Uhrberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="98" to="107" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Moesta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Parham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers in immunology</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">336</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo</title>
		<author>
			<persName><forename type="first">C</forename><surname>Sola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Andre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lemmers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Fuseri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bonnafous</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Blery</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="issue">31</biblScope>
			<biblScope unit="page" from="12879" to="12884" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">NK cell activation by KIR-binding antibody 1-7 F9 and response to HIV-infected autologous cells in viremic and controller HIV-infected patients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Johansson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hejdeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hinkula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Johansson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Romagne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wahren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="158" to="168" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Benson</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Bakan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Collins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Srivastava</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="6387" to="6391" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Preclinical characterization of 1-7 F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells</title>
		<author>
			<persName><forename type="first">F</forename><surname>Romagne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Andre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Spee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Anfossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gauthier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="2667" to="2677" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Kohrt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thielens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Marabelle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Sagiv-Barfi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Chanuc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="678" to="686" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission</title>
		<author>
			<persName><forename type="first">N</forename><surname>Vey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Bourhis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Boissel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bordessoule</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Prebet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Charbonnier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="4317" to="4323" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Impact of a functional KIR2DS4 allele on heterosexual HIV-1 transmission among discordant Zambian couples</title>
		<author>
			<persName><forename type="first">A</forename><surname>Merino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Malhotra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Morton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mulenga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Allen</forename><forename type="middle">S</forename><surname>Hunter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">203</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="487" to="495" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
